丛明华营养示范查房

内容精要：查房实景重现、肿瘤患者营养状况全程管理模式、如何进行营养诊断及确定治疗方案。

DTC术后TSH抑制治疗

讲者：关海霞主任（中国医科大学附属第一医院）讲题：DTC术后TSH抑制治疗

怎样做好甲状腺手术---艺术的追求

讲者：赵文新主任（福建医科大学附属协和医院甲状腺外科）讲题：怎样做好甲状腺手术---艺术的追求

NCCN指南解析

指南那么长，怎么指导临床？每次的更新，依据又是什么？有疑惑吗？别着急！壹生大学邀请了临床一线的专家们，将指南拆分详解，带给您最贴近临床的指南解析。

ETALK核心专家会

中国肝癌领导力论坛精粹

中国肝癌领导力论坛暨拜万戈肝癌上市会于2018年3月18日在上海隆重举办

05 Robert LaCaze-拜耳全球肿瘤研发及业务新方向

Robert LaCaze 总裁拜耳全球肿瘤事业部总裁Robert LaCaze is a senior bio-pharmaceutical executive with more than 28 years of experience in the industry. Throughout his career he has served in multiple operational and strategic roles involving the US, EU, China and Japan.Mr. LaCaze joined Bayer Pharmaceuticals in October 2015 and currently serves as the Executive Vice President and Head of the Oncology Strategic Business Unit (SBU). The Oncology SBU is responsible for all strategy in Bayer’s Oncology Business and consists of: Clinical Development, Regulatory Affairs, Strategic Medical Affairs, Strategic Marketing and Commercialization, Oncology Market Access and Clinical Operations. He is also a member of Bayer’s Pharmaceutical Executive Committee.Prior to joining Bayer, Mr. LaCaze spent over 25 years with Bristol Myers Squibb serving in multiple roles including his two most recent roles of Senior Vice President and Head of Product and Portfolio Strategy for Worldwide Commercialization and Senior Vice President, Global Oncology Commercialization in which he was responsible, with his R&D counterpart, for setting the vision and strategy for the Immuno-Oncology (I-O) franchise. He oversaw the early strategy for Nivolumab and lead the Global Launch of Ipilimumab BMS’s first I-O drug and the Global launch of BMS’s first target therapy, Dasatinib. Both of which have achieved more than $1B in annual sales.Mr LaCaze is a member of AACR and also serves as a member of the College of Business Advisory Board for Louisiana Tech University, his alma mater. He, his wife, and two sons reside in Robbinsville NJ.

03 韩国宏-介入新思路：建立 TACE 技术与靶向药物治疗最佳联合

韩国宏 教授空军军医大学（第四军医大学）西京医院消化介入科主任主任医师、教授、博导亚太原发性肝癌理事会理事（APPLE Council Member）中华医学会放射学分会介入学组副主任委员中国研究型医院学会介入专委会副主任委员中华医学会消化学分会介入协作组副组长卫计委原发性肝癌诊疗规范专家委员会委员（2011 版和 2017 版）2017 年以第一完成人获军队科技进步一等奖2016 年作为主要成员获国家科学进步奖创新团队奖2012 年至 2016 年连续五年荣登中国名医百强榜（介入放射治疗科）2010 年以来作为第一或通讯作者在 Gut、Nat Rev Gastro & Hepatol 、 Hepatology 、 J Hepatol 、 Ann Oncol 、 Clin Cancer Res 、 Radiology、 Thromb & Haemost 等权威杂志发表 SCI 同行评议论文 129 篇

北肿胰腺癌及神经内分泌肿瘤交流

李囡--胰腺net核医学靶向诊疗 王湛博--胰腺癌组织学病理及分子分型的学习与思考李洁--pNEN的诊断和治疗金克敏--胰腺神经内分泌肿瘤的外科治疗谷满仓--分子靶向细胞周期依赖蛋白激酶（CDKs）在胰腺癌治疗中的进展周军--进展期胰腺癌的化疗选择

结直肠癌治疗大师班